Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

INTRODUCTION: Treatment with selective serotonin reuptake inhibitors has been suggested to mitigate amyloid-β (Aβ) pathology in Alzheimer's disease, in addition to an antidepressant mechanism of action. METHODS: We investigated whether chronic treatment with paroxetine, a selective serotonin re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alzheimers Dement (N Y)
Hauptverfasser: Severino, Maurizio, Sivasaravanaparan, Mithula, Olesen, Louise Ø., von Linstow, Christian U., Metaxas, Athanasios, Bouzinova, Elena V., Khan, Asif Manzoor, Lambertsen, Kate L., Babcock, Alicia A., Gramsbergen, Jan Bert, Wiborg, Ove, Finsen, Bente
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2018
Schlagworte:
Featured Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021554/
https://ncbi.nlm.nih.gov/pubmed/29955664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2018.04.005
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge